U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H29N3O2
Molecular Weight 343.4632
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIBUCAINE

SMILES

CCCCOC1=CC(C(=O)NCCN(CC)CC)=C2C=CC=CC2=N1

InChI

InChIKey=PUFQVTATUTYEAL-UHFFFAOYSA-N
InChI=1S/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)

HIDE SMILES / InChI

Molecular Formula C20H29N3O2
Molecular Weight 343.4632
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Dibucaine is used as a local anesthetic for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. Dibucaine is used to temporarily relieve pain and itching due to: hemorrhoids or other anorectal disorders, sunburn, minor burns, minor cuts; scrapes, insect bites, minor skin irritation. This drug acts via blocking of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions through sodium channel blocking. This reversibly stabilizes the membrane and inhibits depolarization, resulting in the failure of a propagated action potential and subsequent conduction blockade.

CNS Activity

Curator's Comment: small amounts of drug likely cross the blood-brain barrier because dibucaine is neurotoxic at higher concentrations in patients

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Nupercainal

Approved Use

temporarily relieves pain and itching due to: - hemorrhoids or other anorectal disorders - sunburn - minor burns - minor cuts- scrapes - insect bites - minor skin irritation
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
23 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIBUCAINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
208 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIBUCAINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11 h
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIBUCAINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Nitric oxide production by the vacuolar-type (H+)-ATPase inhibitors bafilomycin A1 and concanamycin A and its possible role in apoptosis in RAW 264.7 cells.
2006-11
Overexpression of RGPR-p117 enhances regucalcin gene promoter activity in cloned normal rat kidney proximal tubular epithelial cells: involvement of TTGGC motif.
2006-10-01
Involvement of nuclear factor I-A1 in the regulation of regucalcin gene promoter activity in cloned normal rat kidney proximal tubular epithelial cells.
2006-10
Verapamil, a Ca2+ channel inhibitor acts as a local anesthetic and induces the sigma E dependent extra-cytoplasmic stress response in E. coli.
2006-10
Inhibition of scratching behavior associated with allergic dermatitis in mice by tacrolimus, but not by dexamethasone.
2006-09-28
Effects of dibucaine on the endocytic/exocytic pathways in Trypanosoma cruzi.
2006-09
Regulatory effect of exogenous regucalcin on cell function in osteoblastic MC3T3-E1 cells: involvement of intracellular signaling factor.
2006-08
Supramolecular binding of protonated amines to a receptor microgel in aqueous medium.
2006-06-21
Divergence paresis without positional headache: an unusual presentation of cerebrospinal fluid hypovolemia after spinal anesthesia.
2006-06
[Butyrylcholinesterase deficiency: how to analyse the cholinesterase activity in small children?].
2006-06
Effect of various formulation variables on the encapsulation and stability of dibucaine base in multilamellar vesicles.
2006-02-08
Toxicity of polymyxins: a systematic review of the evidence from old and recent studies.
2006-02
False positives and false negatives with a cocaine-specific field test and modification of test protocol to reduce false decision.
2005-12-20
[Anogenital dermatoses--allergic and irritative causative factors. Analysis of IVDK data and review of the literature].
2005-12
Overexpression of RGPR-p117 enhances regucalcin gene expression in cloned normal rat kidney proximal tubular epithelial cells.
2005-12
Pseudocholinesterase polymorphism in an Irish population.
2005-11
Overexpression of regucalcin suppresses cell proliferation in cloned rat hepatoma H4-II-E cells: involvement of intracellular signaling factors and cell cycle-related genes.
2005-08-15
Activation of calcium-independent phospholipase A (iPLA) in brain mitochondria and release of apoptogenic factors by BAX and truncated BID.
2005-08
Prescription pattern for treatment of hemorrhoids under the universal coverage policy of Thailand.
2005-07
Hormonal regulation on regucalcin mRNA expression in cloned normal rat kidney proximal tubular epithelial NRK52E cells.
2005-06-01
Cinchocaine hydrochloride determination by atomic absorption spectrometry and spectrophotometry.
2005-05
Wetting of surfactant solutions by alkanes.
2005-03
Genotyping the butyrylcholinesterase in patients with prolonged neuromuscular block after succinylcholine.
2005-03
Rapid accurate mass desorption electrospray ionisation tandem mass spectrometry of pharmaceutical samples.
2005
Cd2+ versus Ca2+-produced mitochondrial membrane permeabilization: a proposed direct participation of respiratory complexes I and III.
2004-12-07
Role of albumin in osteoblastic cells: enhancement of cell proliferation and suppression of alkaline phosphatase activity.
2004-12
Microfabricated fractal branching networks.
2004-11-01
Protective actions of various local anesthetics against the membrane dysfunction produced by in vitro ischemia in rat hippocampal CA1 neurons.
2004-11
Overexpression of regucalcin suppresses cell death and apoptosis in cloned rat hepatoma H4-II-E cells induced by lipopolysaccharide, PD 98059, dibucaine, or Bay K 8644.
2004-10-15
Preferential partitioning of uncharged local anesthetics into the surface-adsorbed film.
2004-10-10
[Allergy to formaldehyde].
2004-09
[Glucose attenuating local anesthetic-induced hemolysis].
2004-09
A new look at the hemolytic effect of local anesthetics, considering their real membrane/water partitioning at pH 7.4.
2004-08-01
Local anaesthetics--Nupercaine and Amethcaine.
2004-08
Randomized, double-blind trial comparing topical nitroglycerine with xylocaine and Proctosedyl in idiopathic chronic anal fissure.
2004-07-15
Evaluation of antipruritic effects of several agents on scratching behavior by NC/Nga mice.
2004-07-14
Apoptotic-like mitochondrial events associated to phosphatidylserine exposure in blood platelets induced by local anaesthetics.
2004-07
Effect of the glycosphingolipid, GM1 on localization of dibucaine in phospholipid vesicles: a fluorescence study.
2004-07
Some amphiphilic cations block the mitochondrial apoptosis-induced channel, MAC.
2004-06-18
Interaction of serotonin1A receptors from bovine hippocampus with tertiary amine local anesthetics.
2004-06
Probing the mechanism of drug/lipid membrane interactions using Biacore.
2004-05-15
Ethnic differences in the frequency of distribution of serum cholinesterase activity in the Iranian population.
2004-05
Quantitative evaluation of the effects of mitochondrial permeability transition pore modifiers on accumulation of calcium phosphate: comparison of rat liver and brain mitochondria.
2004-04-01
[Cauda equina syndrome following intrathecal dibucaine].
2004-04
Possible mechanism of irreversible nerve injury caused by local anesthetics: detergent properties of local anesthetics and membrane disruption.
2004-04
Anesthesiology, the birth of pharmacogenetics and Werner Kalow.
2004-03
[What we can learn from a case of medical malpractice].
2004-02
p-Bromophenacyl bromide prevents cumene hydroperoxide-induced mitochondrial permeability transition by inhibiting pyridine nucleotide oxidation.
2004
An improvement in segregation of human butyrylcholinesterase phenotypes having the fluoride-resistant variants.
2003-12
[Ionic strength influences hemolytic action of dibucaine hydrochloride].
2003-11
Patents

Sample Use Guides

If possible clean the affected area with mild soap and warm water and rinse thoroughly. Gently dry by patting or blotting with toilet tissue or a soft cloth before applying. Adults and children 12 and over - apply externally to the affected area up to 3 to 4 times a day. Children under 2 - 12 years of age - ask a doctor
Route of Administration: Topical
In Vitro Use Guide
Exposure of spinal nerves to dibucaine reduces the quantity of 3H-proteins, which is transported to a ligature by 72% at 0.5 mM and by greater than 90% at a 1 mM concentration; since 1 mM tetracaine reduces it by 64%, dibucaine is approximately twice as potent as tetracaine at inhibiting transport.
Substance Class Chemical
Created
by admin
on Wed Apr 02 09:30:39 GMT 2025
Edited
by admin
on Wed Apr 02 09:30:39 GMT 2025
Record UNII
L6JW2TJG99
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CINCHOCAINE
INN  
Preferred Name English
DIBUCAINE
HSDB   MI   USP   VANDF  
USAN  
Official Name English
2-Butoxy-N-[2-(diethylamino)ethyl]cinchoninamide
Systematic Name English
DIBUCAINE [USP IMPURITY]
Common Name English
DIBUCAINE [USP MONOGRAPH]
Common Name English
Cinchocaine [WHO-DD]
Common Name English
NSC-159055
Code English
DIBUCAINE [MI]
Common Name English
cinchocaine [INN]
Common Name English
4-QUINOLINECARBOXAMIDE, 2-BUTOXY-N-(2-(DIETHYLAMINO)ETHYL)
Common Name English
2-BUTOXY-N-(2-(DIETHYLAMINO)ETHYL)-4-QUINOLINECARBOXAMIDE
Systematic Name English
DIBUCAINE [HSDB]
Common Name English
CINCHOCAINE [MART.]
Common Name English
2-BUTOXY-N-(2-DIETHYLAMINOETHYL)CINCHONINAMIDE
Systematic Name English
DIBUCAINE [VANDF]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 310.538
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
WHO-ATC D04AB02
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
WHO-VATC QC05AD04
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
NDF-RT N0000185508
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
WHO-ATC S01HA06
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
NCI_THESAURUS C245
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
WHO-VATC QN01BB06
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
WHO-ATC N01BB06
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
WHO-ATC S02DA04
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
CFR 21 CFR 346.10
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
WHO-VATC QS02DA04
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
WHO-VATC QD04AB02
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
WHO-VATC QS01HA06
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
WHO-ATC C05AD04
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
Code System Code Type Description
EVMPD
SUB06287MIG
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY
NDF-RT
N0000171131
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY Allergens [Chemical/Ingredient]
NDF-RT
N0000175629
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY Increased Histamine Release [PE]
DRUG BANK
DB00527
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY
EPA CompTox
DTXSID3045271
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY
PUBCHEM
3025
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY
HSDB
3312
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY
WIKIPEDIA
Cinchocaine
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY
ECHA (EC/EINECS)
201-632-1
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY
FDA UNII
L6JW2TJG99
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY
IUPHAR
7159
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY
DRUG CENTRAL
859
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY
RXCUI
3339
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY RxNorm
NDF-RT
N0000184306
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY Cell-mediated Immunity [PE]
ChEMBL
CHEMBL1086
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY
MERCK INDEX
m4306
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY Merck Index
INN
108
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY
NCI_THESAURUS
C28984
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY
DAILYMED
L6JW2TJG99
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY
MESH
D003992
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY
NSC
159055
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY
CAS
85-79-0
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY
SMS_ID
100000081060
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY
CHEBI
247956
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY
LACTMED
Dibucaine
Created by admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY